Lipid-Based Nanoparticles for Vaccine Applications

Currently available vaccine adjuvants are ineffective against a wide range of infectious pathogens as well as cancers. Therefore, there is a critical demand for new vaccine strategies that can elicit potent cellular and humoral immune responses. Liposomes have been widely examined as vaccine delivery systems because of their safety, low toxicity, and ease of scale-up. However, successful clinical translation of liposomal vaccines has been hampered by their limited potency to induce strong T and B cell responses. In this chapter, we will present two classes of lipid-based nanoparticle systems designed to address limitations of liposomal vaccines and discuss their potential as vaccine delivery systems. The first class of lipid-based nanoparticles presented in this chapter is termed interbilayer-crosslinked multilamellar vesicles. These novel vaccine nanoparticles are stable vehicles that can effectively deliver antigens and adjuvant molecules to antigen-presenting cells in lymphoid tissues and induce robust T and B cell immune responses in vivo. The second class of vaccine nanoparticles is lipoproteins composed of endogenous proteins and lipids. Applications of lipoproteins for vaccine delivery have recently gained much attention due to their safety and multi-faceted functions as endogenous drug delivery vehicles. We provide an overview on the latest advances in this rapidly evolving interdisciplinary area of research, and we discuss biomaterial-based innovations enabled by nanotechnology for improving vaccine design and development.

[1]  R. Titball,et al.  Lipoproteins of Bacterial Pathogens , 2010, Infection and Immunity.

[2]  D. Irvine,et al.  Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. , 2012, ACS nano.

[3]  James J Moon,et al.  Engineering Nano‐ and Microparticles to Tune Immunity , 2012, Advanced materials.

[4]  James J. Moon,et al.  Biomaterials for Nanoparticle Vaccine Delivery Systems , 2014, Pharmaceutical Research.

[5]  D. Irvine,et al.  Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry* , 2013, The Journal of Biological Chemistry.

[6]  Soong Ho Um,et al.  Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. , 2009, Biomacromolecules.

[7]  G. Loots,et al.  The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge , 2013, Biomaterials.

[8]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[9]  T. V. van Berkel,et al.  Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. , 2001, Advanced drug delivery reviews.

[10]  P. Lambert,et al.  Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses , 2012, The Journal of Immunology.

[11]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[12]  Bali Pulendran,et al.  Immunological mechanisms of vaccination , 2011, Nature Immunology.

[13]  J. Villadangos,et al.  Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo , 2007, Nature Reviews Immunology.

[14]  Jonathan F. Lovell,et al.  Lipoprotein-Inspired Nanoparticles for Cancer Theranostics , 2011, Accounts of chemical research.

[15]  P. Hoeprich,et al.  Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. , 2013, Journal of the American Chemical Society.

[16]  Hideyoshi Harashima,et al.  The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[17]  P. Stayton,et al.  pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. , 2013, ACS nano.

[18]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[19]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[20]  H. Kohrt,et al.  A Cpg-loaded Tumor Cell Vaccine Induces Antitumor Cd4 Ϩ T Cells That Are Effective in Adoptive Therapy for Large and Established Tumors Results Cpg Loading Is Required for Effective Vaccination in Tlr9-competent Hosts , 2022 .

[21]  C. Alving,et al.  Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines. , 2009, Vaccine.

[22]  D. Irvine,et al.  Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination , 2013, Science Translational Medicine.

[23]  Ruslan Medzhitov,et al.  Pattern recognition receptors and control of adaptive immunity , 2009, Immunological reviews.

[24]  D. Irvine,et al.  Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine , 2012, PloS one.

[25]  F. Sacks,et al.  Apolipoprotein-mediated pathways of lipid antigen presentation , 2005, Nature.

[26]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[27]  P. Brennan,et al.  Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions , 2013, Nature Reviews Immunology.

[28]  R. Tampé,et al.  Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation , 2008, Nature Immunology.

[29]  N. Ali,et al.  Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[30]  D. Irvine,et al.  Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[31]  R. Bleackley,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[32]  Eric Stern,et al.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. , 2012, Biomaterials.

[33]  T. Ishikawa,et al.  Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. , 2010, Bioconjugate chemistry.

[34]  Yuhua Wang,et al.  Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[35]  K. Kono,et al.  A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. , 2013, Biomaterials.

[36]  O. Joffre,et al.  Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.

[37]  Yifan Ma,et al.  PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[38]  G. Belz,et al.  Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.

[39]  R. Steinman,et al.  Dendritic cell‐targeted protein vaccines: a novel approach to induce T‐cell immunity , 2012, Journal of internal medicine.

[40]  J. Chen,et al.  Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model , 2012, PloS one.

[41]  Michael B. Brenner,et al.  CD1 antigen presentation: how it works , 2007, Nature Reviews Immunology.

[42]  Gregory Gregoriadis,et al.  Liposomes As Immunological Adjuvants and Vaccine Carriers , 1996 .

[43]  A. Khamesipour,et al.  The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. , 2012, Experimental parasitology.

[44]  P. Chong,et al.  A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. , 2009, Vaccine.

[45]  Darrell J Irvine,et al.  Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.

[46]  J C Aguilar,et al.  Vaccine adjuvants revisited. , 2007, Vaccine.

[47]  S. Akira,et al.  Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.

[48]  Joel A. Cohen,et al.  Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting. , 2011, Bioconjugate chemistry.

[49]  R. Houot,et al.  T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. , 2009, Blood.

[50]  T. Long,et al.  Biomimetic design and performance of polymerizable lipids. , 2009, Accounts of chemical research.

[51]  Kyung-Dall Lee,et al.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity. , 2012, Molecular pharmaceutics.

[52]  Yvonne Perrie,et al.  Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[53]  N. Shastri,et al.  In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[55]  N. Fischer,et al.  Enhancing the efficacy of innate immune agonists: could nanolipoprotein particles hold the key? , 2014, Nanomedicine.

[56]  Theresa M Allen,et al.  Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.

[57]  P. Hoeprich,et al.  Kinetic analysis of his-tagged protein binding to nickel-chelating nanolipoprotein particles. , 2010, Bioconjugate chemistry.

[58]  Jeffrey A Hubbell,et al.  Engineering Approaches to Immunotherapy , 2012, Science Translational Medicine.

[59]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[60]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[61]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[62]  Hideyoshi Harashima,et al.  Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.